Previous studies suggest that brain-derived neurotrophic factor and its receptor TrkB are critically involved in the therapeutic actions of antidepressant drugs. We have previously shown that the antidepressants imipramine and fluoxetine produce a rapid autophosphorylation of TrkB in the rodent brain. In the present study, we have further examined the biochemical and functional characteristics of antidepressant-induced TrkB activation in vivo. We show that all the antidepressants examined, including inhibitors of monoamine transporters and metabolism, activate TrkB rapidly in the rodent anterior cingulate cortex and hippocampus. Furthermore, the results indicate that acute and long-term antidepressant treatments induce TrkB-mediated activation of phospholipase-Cg1 (PLCg1) and increase the phosphorylation of cAMP-related element binding protein, a major transcription factor mediating neuronal plasticity. In contrast, we have not observed any modulation of the phosphorylation of TrkB Shc binding site, phosphorylation of mitogen-activated protein kinase or AKT by antidepressants. We also show that in the forced swim test, the behavioral effects of specific serotonergic antidepressant citalopram, but not those of the specific noradrenergic antidepressant reboxetine, are crucially dependent on TrkB signaling. Finally, brain monoamines seem to be critical mediators of antidepressant-induced TrkB activation, as antidepressants reboxetine and citalopram do not produce TrkB activation in the brains of serotonin-or norepinephrine-depleted mice. In conclusion, our data suggest that rapid activation of the TrkB neurotrophin receptor and PLCg1 signaling is a common mechanism for all antidepressant drugs.
INTRODUCTION
Current evidence suggests that antidepressant-induced neuroplastic changes, such as changes in synaptic plasticity, neurogenesis, and synaptogenesis, may at least partially explain the delayed-onset of action of antidepressants (Duman et al, 1997; Manji et al, 2001; Nestler et al, 2002; Castrén, 2005; Castrén et al, 2007) . Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family of neurotrophic factors, and its primary receptor TrkB seem to be particularly relevant factors involved in both the development of mood disorders and the action of antidepressants (Altar, 1999; Nestler et al, 2002; Castrén, 2005; Castrén et al, 2007) . BDNF levels are reduced in mood disorders and preclinical depression models, and long-term antidepressant treatment enhances brain BDNF gene expression and signaling (Nibuya et al, 1995 (Nibuya et al, , 1996 Smith et al, 1995; Russo-Neustadt et al, 1999; Chen et al, 2001b; Karege et al, 2002 Karege et al, , 2005 . A growing body of evidence suggests that BDNF-mediated TrkB signaling is both sufficient and necessary for antidepressant-like behaviors in rodents. Infusion of BDNF or overexpression of TrkB receptors produces antidepressant-like behavioral responses in the preclinical models of behavioral despair (Siuciak et al, 1997; Shirayama et al, 2002; Koponen et al, 2005) . We recently demonstrated that the behavioral effects of two antidepressants, imipramine and fluoxetine (FLX) were abolished in transgenic mice with reduced BDNF levels or inhibited TrkB signaling in brain (Saarelainen et al, 2003) and this observation was subsequently confirmed in forebrain-specific BDNF null mice by using desipramine (Monteggia et al, 2004 (Monteggia et al, , 2007 , which shows a relatively high affinity to norepinephrine transporter (NET) when compared with imipramine and FLX. Furthermore, val/met polymorphism in BDNF gene, which influences the activity-dependent BDNF release (Egan et al, 2003) has recently been associated with mood disorders in humans (Sklar et al, 2002; Lang et al, 2005) . Taken together, these observations suggest that activitydependent and temporal activation of TrkB plays a critical role in the antidepressant response perhaps via the formation and stabilization of new functional synaptic connections.
Chronic but also acute antidepressant treatments produce alterations in BDNF mRNA levels in the rodent anterior cingulate cortex and hippocampus (Nibuya et al, 1995; Zetterström et al, 1999) . In addition, antidepressants block and accelerate the reversion of stress-induced downregulation in BDNF mRNA and protein, respectively (Nibuya et al, 1995; Xu et al, 2004) . Although some studies have reported upregulation of BDNF protein in the rodent hippocampus after prolonged antidepressant treatment (Xu et al, 2003; Wyneken et al, 2006) , some studies have failed to see such significant alterations (Altar et al, 2003; Holoubek et al, 2004) . These findings may reflect the fact that BDNF protein is quite stable inside the cell and undergoes both anterograde and retrograde transport in specific cellular compartments and only a limited amount of BDNF is released activity dependently in neurons (Balkowiec and Katz, 2002; Lu, 2003) . Hence, only a small fraction of the total BDNF protein is extracellular and able to activate TrkB receptors, thus making it difficult to reliably measure extracellular BDNF. To circumvent this problem, we have used autophosphorylation of TrkB receptors as an indirect indicator of BDNF release from neurons. Using this assay, we previously demonstrated that the antidepressants FLX and imipramine, as well as the mood stabilizer, lithium, rapidly autophosphorylate TrkB in the rodent anterior cingulate cortex (Saarelainen et al, 2003; Rantamäki et al, 2006) . TrkB activation is also observed after prolonged antidepressant administration in the rodent brain further pointing out the role of this signaling event mediating the long-term changes of antidepressant treatment (Saarelainen et al, 2003; Rantamäki et al, 2006) .
The aims of the present study were to determine whether rapid induction of TrkB activity is a common factor for pharmacologically diverse antidepressants and to dissect the specific TrkB-mediated signaling events that are downstream of TrkB activity promoted by antidepressants. Furthermore, we extended the previous findings concerning the role of TrkB signaling in regulating the acute behavioral effects of antidepressants in the forced swim test (FST) (Saarelainen et al, 2003; Monteggia et al, 2004) , a prototypic screening test of antidepressant action (Porsolt et al, 1977) , by using selective noradrenergic and serotonergic antidepressants together with TrkB-deficient mice in this paradigm. Finally, given that all clinically used antidepressants regulate monoaminergic signaling, we sought to examine the role of serotonin and norepinephrine (NE) in antidepressant-induced brain TrkB activation in more detail.
MATERIALS AND METHODS

Animals
Adult male Balb/C and C57BL/6 mice were used in the biochemical experiments. In the behavioral studies, transgenic mice overexpressing the truncated form of TrkB receptor (TrkB.T1) and their wild-type (WT) littermates were employed and generated as previously described (Saarelainen et al, 2000) . Animals were group-housed in standard laboratory conditions and food and water (or drug solution) were freely available. All animal experiments were carried out according to the guidelines of the National Institute of Health Guide for the Care and Use of Laboratory Animals and were approved by the Experimental Animal Ethical Committee of University of Helsinki.
Drug Treatments
For the acute antidepressant treatments, animals received a single i.p. injection of antidepressant or saline and tested in the FST (30 min following injection) (Porsolt et al, 1977; Koponen et al, 2005) or killed for biochemical assays (30, 60, or 120 min following drug administration). The following antidepressant drugs and doses were used: FLX-HCl (20-30 mg/kg, Sigma-Aldrich Finland Oy, Helsinki, Finland; OrionPharma Turku, Finland; or kindly provided by GlaxoSmithKline (GSK), Verona, Italy), citalopram-HBr (20 mg/kg, kindly provided by GSK), imipramine-HCl (30 mg/kg, Sigma-Aldrich), clomipramine-HCl (20 mg/kg, Sigma-Aldrich), reboxetine (free base) (20 mg/kg, kindly provided by GSK), and moclobemide (free base) (20 mg/kg, kindly provided by F Hoffmann-La Roche Ltd, Basel, Switzerland). Selected antidepressant doses have been routinely used in rodent models of behavioral despair (Porsolt et al, 1977; Wong et al, 2000; Drago et al, 2001; Weinstock et al, 2002; O'Leary et al, 2007) . Moclobemide and reboxetine were dissolved in 50% DMSO/saline, citalopram in 50% ethanol/saline, others in saline. Saline was used as a control vehicle. For long-term treatments, mice had a free access to either tap water (controls) or 0.08 mg/ml FLX solution for 21 days (Santarelli et al, 2003) . Mouse brain serotonin (5-HT) and NE contents were depleted using pCPA (4-chloro-L-phenylalanine, SigmaAldrich) and DSP-4-HCl (Sigma-Aldrich), respectively. pCPA (in 0.1 M NaOH, pH B8) was injected twice a day (B0900 and B1700 hours) at a dose of 100 mg/kg (i.p.) on 3 consecutive days before and DSP-4 (in saline) at a dose of 50 mg/kg (i.p.) at 7 days before treatment with antidepressants. Control animals received an equal volume saline.
Chemical Analyses
Plasma FLX levels were measured from trunk blood using gas chromatography-mass spectrometry (GC-MS). Briefly, FLX was extracted from 200 ml of plasma by mixing with 5 ml of toluene ( + 150 ng/ml of the internal standard flurazepam) and 200 ml of a buffer (0.5 M Na 2 HCO 3 Â 2H 2 O). After centrifugation, the toluene layer was collected and 15 ml of the derivatization reagent (heptafluorobutyric anhydride, HFBA) was added together with 1 ml of saturated NaHCO 3 . After centrifugation, the toluene layer was evaporated, the residue was dissolved into 50 ml of toluene, and transferred into autosampler vials with inserts. An aliquot of 4 ml of the toluene layer was injected into a GC-MS apparatus consisting of an Agilent (Agilent Technologies, Palo Alto, CA, USA) 6890N gas chromatograph, an Agilent 5973 mass selective detector (EI, positive ions, 70 eV) and an Agilent ChemStation data system. The GC column was a DB-35MS (J&W Scientific Inc., Folsom, CA, USA, length 30 m, internal diameter 0.32 mm and film thickness 0.25 mm). The column temperature was initially 1501C for 1 min, then increased 451C/min to 3301C, with a final hold time of 2 min. MS detection was performed in selected ion monitoring mode. FLX was analyzed as its HFB-derivative. Plasma FLX levels after the acute (30 mg/kg, 60 min) and long-term (0.08 mg/ml, 21 days, ad libitum) FLX treatments were 511.47165.6 and 267.87100.7 ng/ml (average7standard deviation), respectively.
Brain serotonin, NE and dopamine levels were analyzed using high-performance liquid chromatography coupled with electrochemical detection (HPLC-EC) as recently described (Airavaara et al, 2006) . Shortly, a piece of motor cortex was homogenized in a mixture of 0.2 M HClO 4 and antioxidant solution (Kankaanpää et al, 2001), centrifuged (20 800g, 35 min, 41C) , and the supernatants centrifugated again (8600g, 35 min, 41C) through Vivaspin filter concentrators (10 000 MWCO PES; Vivascience AG, Hannover, Germany). The column (Spherisorb s ODS2 3 mm, 4.6 Â 100 mm; Waters, Milford, MA, USA) was kept at 501C with a column heater (Croco-Cil, Bordeaux, France). The mobile phase consisted of 0.1 M NaH 2 PO 4 buffer, 350 mg/l of octane sulfonic acid, 3.5-5% (v/v) CH 3 OH and 450 mg/l EDTA (pH 2.7). The flow rate was 1 ml/min. Filtrate was injected into chromatographic system with a CMA/200 autoinjector (CMA, Stockholm, Sweden). Concentrations of amines were quantified using ESA s CoulArray Electrode Array Detector system (ESA Inc., Chelmsford, MA, USA).
Immunoprecipitation and Western Blot
Mice were killed with CO 2 , brains quickly removed and bilateral anterior cingulate cortex and left hippocampus were dissected on a dish cooled on dry-ice. Samples were immediately homogenized in a lysis buffer (137 mM NaCl, 20 mM Tris, 1% NP-40, 10% glycerol, 48 mM NaF, H 2 O, 2 Â Complete inhibitor mix-(Roche-Applied Science, Indianapolis, IN, USA) and 2 mM Na 2 VO 3 ). After incubation on ice for 15 min, samples were centrifuged (16 100g, 15 min). Protein levels of the collected supernatants were then measured using the Lowry method (Biorad DC protein assay; Lowry et al, 1951) . For Trk receptor immunoprecipitation, 500-600 mg of protein was incubated overnight at + 41C with 5 ml of Trk-antibody (sc-11, Santa Cruz Biotechnology (SCB), Santa Cruz, CA, USA) and immunocomplexes were precipitated with 35 ml of 50% Protein-G Sepharose (in Triton + + : 137 mM NaCl, 20 mM Tris pH 8.0, 48 mM NaF, 0.5% TritonX + 2 Â Complete inhibitor mix (Roche-Applied) + 2 mM Na 3 VO 2 ). Lectin precipitation was carried out essentially as described (Rantamäki et al, 2006) using Wheat Germ Lectin/NP + + (6MB or 4B Sepharose, Amersham Biosciences, Piscataway, NJ, USA or EY Laboratories, San Mateo, CA, USA). Proteins were separated in a SDS-PAGE under reducing conditions (Laemmli buffer: 20% glycerol, 4% SDS, 125 mM Tris (pH 6.8), 10% b-mercaptoethanol, 0.02% bromophenol blue) and blotted to a PVDF membrane (300 mA, 1 h, + 41C). Membranes were incubated with the following primary antibodies: anti-pY674/5 of TrkA (corresponding to pY705/6 in TrkB, 1:1000-2000, Cell Signaling Technology (CST), Danvers, MA, USA), anti-pY705/6 (1:500-1000; Rantamäki et al, 2006) , anti-pY816 of TrkB (1:5000), sc-11 (1:2000, SCB), anti-pCREB (1:1000, CST), anti-cAMP-related element binding protein (CREB) (1:1000, CST) anti-Shc (1:1000, Upstate, Charlottesville, VA, USA), anti-pAKT (1:1000, CST), antiphospholipase-Cg1 (PLCg1) (1:1000, Upstate), and anti-p42/p44-mitogen-activated protein kinase (MAPK) (1:1000, CST). Further, the membranes were washed with TBS/0.1% Tween s (TBST) and incubated with horseradish peroxidase conjugated secondary antibody (1:10 000 in nonfat dry milk, 1 h, RT, BioRad Laboratories, Hercules, CA). After subsequent TBST washes, secondary antibodies were visualized using electrochemiluminescence kits (ECL; Amersham Biosciences) followed by an exposure to X-ray film and/or Fuji LAS-3000 camera (Tamro Medlabs, Vantaa, Finland) for ECL detection.
The Forced Swim Test
TrkB.TKÀ mice (n ¼ 35) and their WT littermates (n ¼ 44) were tested in the FST (Koponen et al, 2005) 30 min after the injection of citalopram (20 mg/kg), reboxetine (20 mg/ kg), or saline without a pre-swim. The behavioral parameter recorded was latency to immobility. The test was carried out in a glass decanter (f 18 cm, height 27 cm) half-filled with water (23711C). During maximum of 6 min observation period, the first period of immobility over 2 s was recorded as the latency to immobility time.
Data Analysis
Immunoblot bands were quantitated using NIH ImageJ 1.32. Statistical analyses were carried out using two-sample two-tailed Student's t-test or with one-or two-way analysis of variance (ANOVA) with Newman-Keuls post hoc test. Criteria for statistical significance was po0.05. In the Western blot analyses, equal loading was confirmed using the Ponceau staining, which was routinely used for normalization, unless otherwise stated. Unless otherwise stated, all data are presented as mean7SEM (standard error of mean) and as percentage of control.
RESULTS
The Acute Effects of Diverse Antidepressants on TrkB Activation in Mouse Brain
Both acute and long-term treatment with the antidepressants imipramine and FLX or mood stabilizer lithium induces autophosphorylation of TrkB in the mouse anterior cingulate cortex (Saarelainen et al, 2003; Rantamäki et al, 2006) . In the present study, we examined whether TrkB activation is a response shared by pharmacologically diverse antidepressants or whether it is specific for antidepressants directed against certain pharmacological targets. TrkB autophosphorylation was measured by Western blot using our previously described antibody (Rantamäki et al, 2006) . Phosphorylation of the tyrosines 705/6 at the autophosphorylation loop is a critical step in the TrkB receptor activation (Huang and Reichardt, 2001 ). Moreover, pY705/6 levels are highly correlated with actual tyrosine kinase activity in vitro (Segal et al, 1996) . Preliminary studies were conducted to first determine the time course of the effects of FLX (30 mg/kg) on hippocampal pY705/6 levels (n ¼ 5-7/group). TrkB activation was increased 30 min after FLX administration and reached the maximal levels within 60 min (Figure 1a ). In line with our previous observations (Saarelainen et al, 2003; Rantamäki et al, 2006) , the Trk protein levels were not altered after acute antidepressant treatment (Figure 1b) . The ability of other antidepressants with different pharmacological profiles to induce TrkB autophosphorylation at the Y705/6 site was then examined. The following antidepressants were tested: the selective serotonin transporter (SERT) blocker citalopram (20 mg/kg), the NE transporter (NET) blocker reboxetine (20 mg/kg), the tricyclic antidepressants clomipramine (20 mg/kg), and imipramine (30 mg/kg) (a positive control; see Saarelainen et al, 2003) , and the monoamine oxidase-A (MAO-A) inhibitor moclobemide (20 mg/kg) (n ¼ 4-7/group). Effects were first investigated at the 30 min time point, and drugs that did not to alter pY705/6 levels at this time point were then re-evaluated at the 60 min time point. All the antidepressants tested significantly increased pY705/6 levels in the anterior cingulate cortex (Figure 2a ) and hippocampus ( Figure 2b ) within 30-60 min of a single injection. None of the treatments influenced the expression levels of total TrkB protein (data not shown).
Antidepressants Increase the Activation of TrkB PLCc1
Site and the Phosphorylation of CREB Phosphorylation of TrkB catalytic domain is considered as an initial step in TrkB receptor activation, which further regulates the phosphorylation and activation of other tyrosines of which Y515 and Y816 has been most extensively studied (Huang and Reichardt, 2001 ). Phosphorylation of Y515 leads to activation of the MAPK and AKT (protein kinase-B) signaling pathways, whereas phosphorylation of tyrosine 816 induces the association of the PLCg1 with this phosphotyrosine and the activation of PLCg1-mediated signaling pathway (Huang and Reichardt, 2001) .
We tested the hypothesis that the TrkB-mediated PLCg1 pathway, a signaling event implicated in synaptic plasticity (Minichiello et al, 2002) , is activated by antidepressant treatment. Activation of PLCg1 was measured by using a polyclonal antibody, which specifically recognizes the phosphorylation of TrkB receptor PLCg1 site (pY816) and by analyzing the interaction of PLCg1 with TrkB by measuring the co-immunoprecipitation of these proteins. Significant increase in pY816-band immunoreactivity was observed 60 min after a single 20 mg/kg FLX treatment (Figure 3a) . Similar induction in pY816 levels was observed after the acute reboxetine (20 mg/kg, 30 min, 7), citalopram (20 mg/kg, 60 min, 7), and imipramine treatments (data not shown). Furthermore, we observed that acute FLX treatment tend to increase the association of PLCg1 with Trk receptors (Figure 3b ), albeit the difference did not reach a statistically significant value. Given the importance of prolonged antidepressant treatment for clinical recovery from depression, association of PLCg1 with Trk was also analyzed after long-term FLX (0.08 mg/ml FLX in drinking solution, 21 days) and water administration (n ¼ 8-9/ group). In the drug treatment group, average plasma FLX levels were clinically relevant being 268733 ng/ml (Altamura et al, 1994) at the time of brain tissue dissection. This FLX administration protocol has been previously shown to produce long-term alterations in neuroplasticity and animal behavior (Santarelli et al, 2003) . Importantly, a significant increase in the association of PLCg1 with Trk was observed in the hippocampal samples when compared with control animals (Figure 3c ) and this change coincided with increased autophosphorylation of TrkB receptor (see below, Figure 4f ). Additional Western blot analyses revealed that PLCg1 or TrkB protein levels were not altered after prolonged antidepressant treatments when compared with the control group thus discounting the possibility that changes observed after prolonged antidepressant treatments were due to alterations in PLCg1 or TrkB protein levels (data shown partially in Figure 3d ). Taken together, these data indicate that antidepressant-induced TrkB activation leads to increased PLCg1 signaling.
Although antidepressants and lithium readily induce autophosphorylation of the Y705/6 site, the phosphorylation of tyrosine 515 (pY515), the interaction site for the Shc adaptor protein is not altered by these drugs (Saarelainen et al, 2003; Rantamäki et al, 2006) . We have now confirmed that FLX fails to induce pY515 in the mouse hippocampus not only 30 min after administration, but also 60 and 120 min following FLX administration (30 mg/kg, n ¼ 5-7/group) (Figure 4a ). These observations, together with earlier findings Saarelainen et al, 2003; Rantamäki et al, 2006; Figure 3a) , clearly indicate that the phosphorylation status of different tyrosine residues in TrkB are differentially and independently regulated in vivo. In order to investigate further the actions of antidepressants on Y515 signaling of TrkB, the phosphorylation status of AKT and MAPK from hippocampal samples obtained from mice acutely treated with FLX (30 mg/kg, 60 min) or saline were examined (n ¼ 5-7/group). In agreement with lack of changes in pY515 levels after acute FLX treatment, no changes were observed in the tissue levels of either p42/p44-MAPK or pAKT when compared with saline treated animals (Figure 4b and c) . Next, the phosphorylation of Shc-binding (Y515) site and the interaction of the three Shc adaptors with Trk receptors following 3 weeks of FLX (0.08 mg/ml FLX in drinking solution) or water was measured (n ¼ 8-9/ group). In Trk immunoprecipitated pool of proteins, no differences were observed in Shc interaction between treatment groups (Figure 4d ). Similarly to acute antidepressant treatment, long-term FLX treatment did not change the phosphorylation status of Y515 site in TrkB (Figure 4e ). In the same samples, pY705/6 levels were significantly upregulated when compared with control mice (Figure 4f) , thus discounting the possibility that chronic drug administration desensitizes the pY705/6 response (see Saarelainen et al, 2003) . Together these findings indicate that acute and long-term antidepressant treatment increases TrkB receptor activity, which further leads to the activation of TrkB-PLCg1 signaling in the mouse brain without significantly altering the Shc-mediated signaling pathways of TrkB.
CREB signaling is a critical mediator of the long-term antidepressant response (Duman et al, 1997; Nestler et al, 2002; Carlezon et al, 2005) . CREB and BDNF signaling are tightly coupled, as CREB phosphorylation increases BDNF expression and TrkB activation leads to the phosphorylation and activation of CREB. Minichiello et al (2002) have recently shown that the Y816 site of TrkB, in contrast to Y515 site, is an important regulator of CREB phosphorylation in vitro. Consequently, we asked whether the antidepressant-induced enhancement of TrkB-PLCg1 signaling results in increased phosphorylation of CREB in vivo. Both acute and long-term FLX treatments significantly increased the pCREB levels in the mouse hippocampus (Figure 5a and b). Similar induction in hippocampal pCREB levels were observed after the acute reboxetine (20 mg/kg, 30 min) and citalopram (20 mg/kg, 60 min) treatments (Reboxetine 187.04717.98%, po0.01; Citalopram 368.25753.33%, po0.005; % of Saline; n ¼ 5/group; Student's t-test). These data are consistent with a model where antidepressants rapidly induce the autophosphorylation of TrkB, which through PLCg1 signaling, activates CREB. This model is supported by our previous observation that imipramineinduced increase in pCREB is blunted in the cingulate cortex of mice overexpressing the dominant-negative TrkB receptor in brain (Saarelainen et al, 2003) . 
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The Behavioral Effects of Citalopram and Reboxetine in TrkB.T1 Overexpressing Mice
Recently, we and others have shown that the administration of BDNF or overexpression of TrkB produce antidepressant-like effects in rodent depression models (Siuciak et al, 1997; Shirayama et al, 2002; Koponen et al, 2005) , whereas TrkB signaling is essential for the behavioral effects of noradrenergic and serotonergic antidepressants in the FST (Saarelainen et al, 2003; Monteggia et al, 2004) . As the antidepressant treatments (imipramine, FLX, and desipramine) used in the previous experiments did not clearly differentiate between brain 5-HT and NE systems, we examined the effects of acute treatment with the selective SERT blocker (citalopram, 20 mg/kg; Bymaster et al, 2002) and the selective NET blocker (reboxetine, 20 mg/ kg; Page and Lucki, 2002) in WT and TrkB-deficient mice (TrkB.TKÀ) when tested in the FST. Both citalopram and reboxetine significantly increased latency to immobility in WT mice in the FST ( Figure 6 ). As previously reported (Saarelainen et al, 2003) , the behavior of saline-treated TrkB.TKÀ mice in FST was comparable to their WT littermates ( Figure 6 ). In agreement with our previous findings with imipramine and FLX (Saarelainen et al, 2003) , the acute behavioral effects of citalopram in the FST were essentially abolished in TrkB.TKÀ mice (Figure 6 ). In Antidepressants activate brain TrkB receptors T Rantamäki et al striking contrast, however, acute reboxetine treatment significantly increased the latency to immobility time in TrkB.TKÀ mice in a manner similar to reboxetine-treated WT mice (Figure 6 ). Altogether, the present results suggest that the acute behavioral effects of serotonergic agent in the FST are crucially dependent on TrkB signaling. However, the acute behavioral effects of highly selective noradrenergic antidepressant reboxetine in the FST appear to be partially mediated through TrkB-independent neuronal circuits.
The Role of Monoamines in Antidepressant-Induced Brain TrkB Activation
Antidepressants that block monoamine transporters produce rapid elevation of extracellular monoamines, particularly 5-HT and NE, in the rodent forebrain. To investigate the role of these monoamines in antidepressant-induced brain TrkB activation, brain 5-HT or NE content was depleted using pCPA (see Materials and methods) or DSP-4 (see Materials and methods), respectively, prior acute treatment with reboxetine (20 mg/kg, 30 min), citalopram (20 mg/kg, 60 min), and saline (n ¼ 4-7/group). Reboxetine and citalopram are among the most selective blockers for NET and SERT, respectively. As shown in Table 1 , DSP-4 and pCPA robustly diminished tissue NE and 5-HT contents, respectively, in the mouse cortex. In sham animals, both citalopram and reboxetine induced significant activation of TrkB receptors, measured as phosphorylation of TrkB PLCg1 site (Figure 7) . Interestingly, in both DSP-4 and pCPA pre-treated mice, reboxetine and citalopram failed to alter the phosphorylation status of TrkB PLCg1 site (Figure 7 ). These findings suggest that serotonergic and noradrenergic systems are critically involved in antidepressant-induced TrkB activation in the mouse brain.
DISCUSSION Brain TrkB Activation is Induced by Different Antidepressants
The present study demonstrates that a variety of antidepressants irrespective of their pharmacological classifica- Figure 5 Effects of acute (30 mg/kg, 60 min, n ¼ 5; left) and long-term (0.08 mg/ml in drinking water, 3 weeks, n ¼ 9; right) FLX treatment on hippocampal CREB phosphorylation (shown as ratio of pCREB/CREB). *po0.05, two-tailed Student's t-test. to the first period of immobility longer than 2 s. ***, **, *, po0.005, o0.01, and o0.05, respectively, from the respective controls, two-way ANOVA with Newman-Keuls post hoc test, n ¼ 10-16/group. Abbreviations: SAL, saline; pCPA, 4-chloro-L-phenylalanine; NE, norepinephrine; 5-HT, serotonin; DA, dopamine. Data are presented as average ng/mg7SEM. **, ***, po0.01 and o0.005, respectively, Student's t-test.
Figure 7
Role of serotonin and NE in antidepressant-induced TrkB activation (measured as phosphorylation of TrkB PLCg1 site: pY816) in mouse anterior cingulate cortex. Phospho-Trk levels were analyzed from pool of glycosylated proteins as described in the Materials and methods and are normalized against total Trk levels. Data are presented as mean7SEM and as % of SAL/SAL values. *, ***, po0.05 and o0.005, respectively, as compared with the respective controls, two-way ANOVA with NewmanKeuls post hoc test, n ¼ 4-7/group.
Antidepressants activate brain TrkB receptors T Rantamäki et al tion activate in behaviorally effective doses (Porsolt et al, 1977; Wong et al, 2000; Drago et al, 2001; Weinstock et al, 2002; O'Leary et al, 2007) TrkB receptors in the rodent brain. Similar changes in TrkB activity have also been observed after acute lithium treatment (Rantamäki et al, 2006) . These effects are rapid and observed within 1 h of administration and persist following long-term drug administration (Saarelainen et al, 2003; Rantamäki et al, 2006) . Importantly, in addition to the conventional antidepressants, the monoamine oxidase inhibitor moclobemide produced significant changes in brain TrkB activity. Ligand-induced dimerization is the best characterized mechanism, which induces autophosphorylation and activation of TrkB and, therefore, our data suggest that antidepressants induce a rapid increase in BDNF release. However, as the majority of brain BDNF is intracellular, total brain BDNF does not reliably reflect its release and unfortunately, extracellular BDNF cannot yet be directly measured in a reliable manner. Indeed, we have failed to observe any changes in the levels of BDNF protein in the anterior cingulate cortex after imipramine and lithium treatment, two treatments that reliably induce TrkB autophosphorylation in the same brain regions (Saarelainen et al, 2003; Rantamäki et al, 2006) . Furthermore, although chronic treatment with a variety of antidepressants increases BDNF mRNA levels in brain (Nibuya et al, 1995) , increases in BDNF protein levels by antidepressant treatments have not been consistently reported (Altar et al, 2003; Holoubek et al, 2004) . These data suggest that antidepressants increase BDNF release and increased BDNF mRNA levels reflect a need to replenish stores of released BDNF. In agreement, a recent study demonstrated that chronic FLX treatment increased TrkB autophosphorylation in signaling endosomes but decreased TrkB protein in synaptic membranes (Wyneken et al, 2006) , which is consistent with the BDNF-induced downregulation of synaptic TrkB (Carter et al, 1995; Haapasalo et al, 2002) . However, we cannot rule out the possibility that antidepressants increase TrkB signaling without influencing BDNF release. Increased intracellular cAMP or membrane depolarization have been shown to increase the membrane localization of TrkB thus enhancing the ability of BDNF to induce TrkB autophosphorylation (Meyer-Franke et al, 1998; Haapasalo et al, 2002; Du et al, 2003; Ji et al, 2005) . Furthermore, some G-protein-coupled receptors have been shown to transactivate TrkB receptors independently of BDNF (Lee et al, 2002a; Lee et al, 2002b; Berghuis et al, 2005) . Finally, as NT-3 (and NT-4/5) is a low-affinity ligand for TrkB, antidepressants may induce TrkB activation by enhancing the effects of this neurotrophin (see Lewis et al, 2006) . Whether these molecular mechanisms are involved in antidepressant-induced TrkB activation, remains to be investigated.
Acute and Long-Term FLX Treatments Induce CREB Phosphorylation and Activation of TrkB-Mediated PLCc1 Pathway
Signal transduction pathways activated by chronic antidepressant treatments have been intensively investigated (Duman et al, 1997; Manji et al, 2001; Coyle and Duman, 2003) , but less is known about the pathways that are activated acutely by antidepressants. TrkB receptors activate several intracellular signaling cascades that can be regulated independently of each other, among them, the MAPK, AKT, and PLCg1 pathways are best characterized (Huang and Reichardt, 2001 ). The present study revealed that acute and long-term antidepressant treatments increased the phosphorylation of TrkB PLCg1 site and its interaction with PLCg1. This finding is supported by the recent observation that pretreatment of primary cortical cultures with imipramine augment BDNF-induced association of TrkB with PLCg1 and thus increases the activation of PLCg1 (Yagasaki et al, 2006) . Importantly, pY816 antibody used in the present study differentiates between different Trk family members, and thus, we were able to clearly demonstrate that antidepressants activate brain TrkB receptors. Interestingly, site-directed mutagenesis studies indicate that the TrkB-PLCg1 pathway is more important for the long-term potentiation than the Shcmediated pathways (Minichiello et al, 2002) . Furthermore, transgenic mice overexpressing TrkB receptors in brain show enhanced learning and increased PLCg1 pathway activity, but no change in the MAPK pathway (Koponen et al, 2004) . Importantly, these mice also show an antidepressant-like behavioral response in the FST (Koponen et al, 2005) , which further supports the association of the TrkB-PLCg1 pathway in antidepressant response. In conclusion, antidepressant-induced TrkB autophosphorylation appears to specifically activate the PLCg1 pathway in hippocampus, a pathway associated with synaptic plasticity in this brain region (Minichiello et al, 2002) .
We did not find any evidence of increased or decreased activity of the MAPK or AKT pathways after acute or chronic FLX treatment in the hippocampus. This observation is consistent with the lack of alteration in the autophosphorylation of the TrkB Shc binding site, which mediates the activation of these signaling pathways (Saarelainen et al, 2003; Rantamäki et al, 2006) . Previous studies on the role of MAPK pathway in the mechanism of antidepressant action have yielded conflicting results (Mercier et al, 2004; Tiraboschi et al, 2004; Fumagalli et al, 2005) . The role of the pathways initiated by the TrkB Shc binding site have been extensively studied in vitro (Huang and Reichardt, 2001 ), but the replacement of the tyrosine 515 with a phenylalanine (which abolished the shc binding) in transgenic mice produced an unexpectedly mild phenotype (Minichiello et al, 2002) , suggesting that other signaling pathways can largely compensate for the lack of MAPK pathway activation in vivo. Interestingly, whereas imipramine pretreatment augments BDNF-induced activation of TrkB-PLCg1 signaling in vitro no changes are observed in BDNF-induced activation of MAPK and AKT pathways (Yagasaki et al, 2006) .
Concomitant with increased activity of TrkB and PLCg1, enhanced phosphorylation of CREB was also observed. This is a particularly interesting finding, as CREB plays an important role in antidepressant-induced plastic and behavioral responses. Overexpression of CREB in the hippocampus induces antidepressant-like behavioral effects in rodents (Chen et al, 2001a) . Moreover, antidepressants induce the phosphorylation and activation of CREB in the rodent and human brain (Frechilla et al, 1998; Thome et al, 2000; Chen et al, 2001b; Conti et al, 2002; Saarelainen et al, 2003; Itoh et al, 2004; Tiraboschi et al, 2004; Laifenfeld et al, 2005) . Moreover, Conti et al (2002) demonstrated that CREB is required for antidepressant-induced increases in BDNF mRNA levels. Although a variety of intracellular signaling events regulate CREB phosphorylation (Carlezon et al, 2005) , there is a tight link between TrkB activity and CREB phosphorylation (Minichiello et al, 2002; Saarelainen et al, 2003; Rantamäki et al, 2006) . Our data are consistent with a model whereby antidepressant-induced TrkB autophosphorylation activates CREB through the PLCg1-mediated pathway in rodent hippocampus. A report showing that PLCg1-Ca 2 + pathway is the major signaling event mediating TrkB-induced CREB phosphorylation is consistent with this model (Minichiello et al, 2002) .
The Behavioral Effects of Serotonergic Antidepressants are Mediated through TrkB-Dependent Neuronal Networks BDNF-mediated TrkB signaling appears to be critically involved in the behavioral effects of antidepressants in the rodent models of behavioral despair (Hoshaw et al, 2005; Monteggia et al, 2004; Koponen et al, 2005; Saarelainen et al, 2003; Shirayama et al, 2002; Siuciak et al, 1997 Figure 6 ). These findings may be however related to gender differences, as a recent study by Monteggia et al (2007) revealed a depressive-like behavior in female but not in male mice in the FST and in the sucrose preference test. Given that a variety of antidepressants increase brain TrkB signaling (Figure 2 ) and that TrkB signaling seem to have a key role in mediating the behavioral effects of antidepressants in the FST (Saarelainen et al, 2003; Monteggia et al, 2004) , we examined the role of TrkB signaling in the behavioral effects of highly selective SERT and NET blocking antidepressants in this test. In agreement with our previous findings with FLX (Saarelainen et al, 2003) , the behavioral effects of a specific serotonergic antidepressant citalopram were prevented in the dominantnegative TrkB.T1 overexpressing mice (which have stably reduced TrkB signaling) (Saarelainen et al, 2003) . In striking contrast, acute treatment with a specific noradrenergic antidepressant reboxetine produced similar behavioral responses in both transgenic and WT mice, even though reboxetine acutely increased TrkB autophosphorylation. This is an interesting finding, as previous studies by Monteggia et al (2004 Monteggia et al ( , 2007 have shown that the behavioral effects of tricyclic antidepressant desipramine (shows more affinity against the NET compared with SERT) were absent in forebrain-specific conditional BDNF knockout mice. It is currently unclear whether the apparent discrepancy between the effects of reboxetine and desipramine in the FST are related to the higher selectivity of reboxetine towards NET, or whether this effect reflects differences in the transgenic mouse models used in the experimental procedures. Nevertheless, these results confirm the critical role of TrkB signaling in the mechanism of at least serotonergic antidepressants. In future studies, it would be informative to extend studies concerning the interactions between antidepressants and TrkB signaling to behavioral paradigms, which more reliably measure therapeutic actions of antidepressant drugs.
The Role of Serotonin and NE in Antidepressant-Induced TrkB Activation
The antidepressants tested in the present study produce a significant and rapid enhancement of extracellular 5-HT and/or NE levels in rodent brain, albeit by different mechanisms, and these responses are considered central for the mechanism of antidepressant drugs (Pozzi et al, 1999; Bymaster et al, 2002; Page and Lucki, 2002) . For example, antidepressant-induced acute behavioral effects in the tail suspension test and FST are diminished in monoamine-depleted mice (Page et al, 1999; Cryan et al, 2004) . The present study investigated the role of brain monoamines in antidepressant-induced TrkB activation. We found that pretreatment with monoamine depleting agents pCPA and DSP4 abolished the ability of reboxetine and citalopram to induce rapid TrkB activation in the mouse anterior cingulate cortex. These results suggest that increased extracellular monoamine levels induced by antidepressants mediate the effects of these drugs on brain TrkB activation.
In conclusion, the results of the present study suggest that activation of TrkB signaling may be a common effect of all antidepressant drugs. Antidepressant-induced rapid changes in extracellular monoamine levels seem to be critical mediators of antidepressant-induced TrkB activity. Through the rapid activation of TrkB-PLCg1-CREB signaling, antidepressants could initiate plastic responses in critical neural circuits and these changes may be important for clinical antidepressant response.
